Arbutus Biopharma (ABUS) has released an update.
Arbutus Biopharma, a company specializing in treatments for chronic hepatitis B, is set to participate in an online fireside chat, showcasing its developments in RNAi therapeutics and PD-L1 inhibitors. The company is advancing its promising therapeutic imdusiran into a Phase 2b clinical trial while evaluating another compound, AB-101, in early clinical trials.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.